Loading
Life sciences · Journal article
Ophthalmology and Therapy · September 22, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Axial elongation varies among adolescents receiving myopia-control treatment, but the contribution of systemic metabolic and skeletal muscle-related characteristics remains uncertain. We examined these associations, treating recorded glucagon-like peptide 1 receptor agonist (GLP-1RA) status as a clinical marker rather than an independent drug exposure. This retrospective study included 3270 adolescents aged 7–18 years receiving single-vision spectacles, defocus incorporated multiple segments (DIMS) lenses, or orthokeratology. The primary outcome was annual axial elongation; composite treatment failure was exploratory. Multivariable regression, spline models, treatment-stratified analyses, and stabilized inverse probability of treatment weighting (IPTW) were performed. Primary adjusted analyses included 2267 complete cases. The revised exploratory muscle-vulnerability score excluded GLP-1RA status and duration. Among 3270 participants, 484 had recorded GLP-1RA use and showed greater obesity and insulin-resistance burden and less favorable muscle and activity profiles. In the comprehensive model, BMI z -score ( β = 0.020 mm/year per unit; 95% CI 0.014–0.026) and HOMA-IR ( β = 0.007 mm/year per unit; 95% CI 0.004–0.009) were associated with greater annual axial elongation. Skeletal muscle index was not independently associated, whereas handgrip strength showed a nonlinear association ( P for nonlinearity = 0.002). Recorded GLP-1RA status was associated with 0.040 mm/year greater elongation (95% CI 0.031–0.049), without heterogeneity across myopia-control strategies ( P for interaction = 0.646). After IPTW and comprehensive adjustment, the estimate attenuated to 0.032 mm/year (95% CI 0.021–0.043), with residual imbalance in four of 17 covariates. Associations with exploratory composite treatment failure were statistically uncertain in the comprehensive model (OR 1.23; 95% CI 0.93–1.63) and after IPTW (OR 1.17; 95% CI 0.80–1.70). Metabolic vulnerability was associated with modestly greater annual axial elongation, although the clinical importance of the observed difference remains uncertain. Recorded GLP-1RA status identified a metabolically higher-risk subgroup but did not establish a drug effect. Muscle-related findings were not uniform, and residual confounding remained.